retatrutide fatty liver disease was alleviated by Lilly's 'triple-G' obesity drug Retatrutide: A Triple Agonist Shaping

Risk factors for pancreatic cancer include advancing age, smoking, chronic pancreatitis (not typically acute pancreatitis), family history, obesity, and diabetes itself

Whilst mild and transient GI symptoms are common with GLP-1 receptor agonists and are generally not a cause for alarm, certain symptoms warrant prompt medical attention

The early data suggests it could be more effective for blood sugar control, but it cannot replace Ozempic right now because it is not approved

Smith SK, Perito ER

CagriSema vs Retatrutide comparison for 2026: mechanisms, clinical trial status, weight loss data, diabetes relevance, tolerability, and approval outlook

For timing optimization , consider administering the nasal spray 10-15 minutes before meals